Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis

Alice Horisberger,Alec Griffith,Joshua Keegan,Arnon Arazi,John Pulford,Ekaterina Murzin,Kaitlyn Howard,Brandon Hancock,Andrea Fava,Takanori Sasaki,Tusharkanti Ghosh,Jun Inamo,Rebecca Beuschel,Ye Cao,Katie Preisinger,Maria Gutierrez-Arcelus,Thomas M. Eisenhaure,Joel Guthridge,Paul J. Hoover,Maria Dall’Era,David Wofsy,Diane L. Kamen,Kenneth C. Kalunian,Richard Furie,Michael Belmont,Peter Izmirly,Robert Clancy,David Hildeman,E. Steve Woodle,William Apruzzese,Maureen A. McMahon,Jennifer Grossman,Jennifer L. Barnas,Fernanda Payan-Schober,Mariko Ishimori,Michael Weisman,Matthias Kretzler,Celine C. Berthier,Jeffrey B. Hodgin,Dawit S. Demeke,Chaim Putterman,Accelerating Medicines Partnership: RA/SLE Network,Michael B. Brenner,Jennifer H. Anolik,Soumya Raychaudhuri,Nir Hacohen,Judith A. James,Anne Davidson,Michelle A. Petri,Jill P. Buyon,Betty Diamond,Fan Zhang,James A. Lederer,Deepak A. Rao
DOI: https://doi.org/10.1101/2024.01.14.575609
2024-03-09
Abstract:Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half of patients achieve complete renal response with standard immunosuppressants. Identifying non-invasive, blood-based pathologic immune alterations associated with renal injury could aid therapeutic decisions. Here, we used mass cytometry immunophenotyping of peripheral blood mononuclear cells in 145 patients with biopsy-proven LN and 40 healthy controls to evaluate the heterogeneity of immune activation in patients with LN and to identify correlates of renal parameters and treatment response. Unbiased analysis identified 3 immunologically distinct groups of patients with LN that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at one year. Patients with enriched circulating granzyme B T cells at baseline showed more severe disease and increased numbers of activated CD8 T cells in the kidney, yet they had the highest likelihood of treatment response. A second group characterized primarily by a high type I interferon signature had a lower likelihood of response to therapy, while a third group appeared immunologically inactive by immunophenotyping at enrollment but with chronic renal injuries. Main immune profiles could be distilled down to 5 simple cytometric parameters that recapitulate several of the associations, highlighting the potential for blood immune profiling to translate to clinically useful non-invasive metrics to assess immune-mediated disease in LN.
Immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: to identify different renal pathological features and treatment outcomes in patients with lupus nephritis (LN) through blood immunophenotyping. Specifically, the study aims to perform immunophenotyping on peripheral blood mononuclear cells (PBMCs) by high - throughput mass cytometry to evaluate the heterogeneity of immune activation in LN patients and identify markers related to renal function parameters and treatment response. ### Research Background Lupus nephritis is a common and serious complication of systemic lupus erythematosus (SLE), affecting more than 40% of SLE patients and significantly increasing SLE - related morbidity and mortality. Although there has been progress in understanding the inflammatory process of nephritis, these advances have not yet been translated into improved renal function outcomes. Currently, less than half of LN patients receiving standard immunosuppressive treatment achieve a complete renal function response within one year, and 10% - 30% of patients progress to end - stage renal disease. ### Research Objectives 1. **Identify non - invasive blood immune markers**: Identify non - invasive markers related to kidney injury through changes in the phenotype of immune cells in blood samples to assist in treatment decision - making. 2. **Evaluate the relationship between immunophenotype and treatment response**: Determine the differences in treatment responses of LN patients with different immunophenotypes, thereby providing a basis for personalized treatment. ### Main Findings - **Heterogeneity of immunophenotypes**: The study analyzed PBMCs from 145 LN patients and 40 healthy controls by mass cytometry and identified three immunologically distinct patient groups (G0, G1, and G2). - **Characteristics of different groups**: - **G0**: Includes all healthy controls and a small number of LN patients, and the immunophenotype of these patients is similar to that of healthy controls. - **G1**: Mainly shows high type I interferon (IFN) signals, and these patients have a poor response to treatment. - **G2**: Mainly shows an increase in granzyme B+ T cells in circulation, and although these patients have more severe diseases, they have the best response to treatment. - **Relationship between immune cells and renal pathology**: The study also found that patients with different immunophenotypes have significant differences in renal pathological features, urinary proteomics, and treatment response. ### Conclusion Through blood immunophenotyping, the immunological characteristics of different LN patients can be identified, and these characteristics are closely related to renal pathology and treatment response. This makes it possible to develop non - invasive clinical indicators, which is helpful for more accurate assessment and management of immune - mediated diseases in LN patients.